New Crohn’s disease therapy on its way

In a new study on a drug called Stelara (ustekinumab) it was seen that 40% patients with moderate to severe Crohn's disease responded. Stelara, which is already approved to treat psoriasis, is a human interleukin (IL)-12 and IL-23 antagonist marketed by Centocor Ortho Biotech Inc. The study findings were presented at Digestive Disease Week 2011.

For the study 526 patients were recruited and almost half had received TNF-inhibitors in the past, but didn't see a marked improvement in their symptoms. Stelara was given to patients intravenously and their response was measured by the Crohn's Disease Activity Index (CDAI). Of the group that received 6 mg/kg of Stelara, 40% saw a 100 point drop in their CDAI scores. At 22 weeks into the study, about 70% of patients receiving Stelara were still seeing an improvement in their symptoms, compared to 42% who were receiving placebo or dummy.

Stelara was considered to be tolerated well by the patients in the study, and reactions at the IV site were neither common nor serious. The next step for the study of this drug in Crohn's disease is a more advanced Phase 3 study.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2020, April 03). New Crohn’s disease therapy on its way. News-Medical. Retrieved on June 06, 2023 from

  • MLA

    Mandal, Ananya. "New Crohn’s disease therapy on its way". News-Medical. 06 June 2023. <>.

  • Chicago

    Mandal, Ananya. "New Crohn’s disease therapy on its way". News-Medical. (accessed June 06, 2023).

  • Harvard

    Mandal, Ananya. 2020. New Crohn’s disease therapy on its way. News-Medical, viewed 06 June 2023,


  1. Trey Junkin Trey Junkin United States says:

    Dealing with a disease as body wide as Crohn's, impacts not only our bodies but also our minds. It is affecting people of all ages, and even young ones now. There is a lot of promising research on new therapies and technologies that may help end chrons desease very soon. Holistic and Alternative doctors use a few treatments that seem to be working really well to give people back their normal lives. Let's hope this great work continues successfully!

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study identifies the essential genetic and immunologic perturbations occurring in patients with long COVID lung fibrosis